Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Comment by dollarhunteron Feb 15, 2005 9:05am
93 Views
Post# 8593003

RE: Conference call Thurs.... Phase 11 starting!

RE: Conference call Thurs.... Phase 11 starting!They continue to discover more positives about Exherin. "The Company now believes that ADH-1 may have two modes of anti- tumor activity - targeting both the cells of the tumor vessels as well as the tumor cells themselves" The next phase will enroll 200 patients. I think even you SS might be pleased with that number. As well they are increasing dosages without problems, another positive. "An update on the European Phase Ib/II trial, where enrollment is already underway using a denser drug administration schedule of weekly dosing. " Things will start happening soon with phase11 trials starting soon. "The first Phase II study, described above, is expected to begin in the second quarter of 2005. In total, the Company expects to enroll approximately 200 or more patients with N-cadherin positive tumors in its Phase II program." I think we might have seen the bottom of this thing and should head north of here. If positive results come from phase11 [ and why would we think they wouldn't given what's happened so far] this thing could take off like a rocket. Our patience might very well be rewarded yet. Regards, DH
Bullboard Posts